196 results
8-K/A
EX-99.1
INVA
Innoviva Inc
28 Oct 22
Completion of Acquisition or Disposition of Assets
4:22pm
transferred to the Buyer
Noncontrolling interest
Pre-tax gain of the Sale offset by transaction costs (1)
Estimated tax expense on the gain of the Sale offset … by estimated transaction costs
After-tax gain of the Sale offset by transaction costs
(1) Reflects $266.7 million related to the gain on the Sale
8-K
EX-99
INVA
Innoviva Inc
8 Feb 07
Results of Operations and Financial Condition
12:00am
program in complicated skin and skin structure infections (cSSSI) partially offset by higher stock-based compensation expense associated … partially offset by the impact of SFAS 123(R). For the full year 2006, total research and development costs were $166.6 million, an increase of $28.6
8-K
EX-99
INVA
Innoviva Inc
23 Jul 09
Results of Operations and Financial Condition
12:00am
and facilities related costs were lower compared to the same period last year due to the reduction in force announced in April 2008 and were offset … was primarily due to cash used in operations that was partially offset by $13.6 million in milestone and reimbursement payments received from Astellas
8-K
EX-99
INVA
Innoviva Inc
26 Jul 07
Results of Operations and Financial Condition
12:00am
by higher costs of non-officer incentive programs and costs of our two Phase 2 clinical programs with TD-1792 and TD-5108, partially offset by lower … , marketing expenses, and costs associated with the GSK call/put provision preparation offset by a decrease in stock-based compensation expenses
8-K
EX-99
INVA
Innoviva Inc
26 Oct 06
Results of Operations and Financial Condition
12:00am
associated with SFAS 123(R) offset by lower external research and development costs associated with our Phase 3 programs for telavancin. Total … during the quarter. This decrease was primarily due to cash usage of approximately $36.4 million during the third quarter offset by the receipt
8-K
EX-99
t3n39 qyyq
15 Feb 11
Results of Operations and Financial Condition
12:00am
8-K
EX-99.1
vpcb6 4bgx1snx46g0y
8 Mar 22
Innoviva Announces Proposed Offering of $200 Million of Convertible Senior Notes
5:15pm
8-K
EX-99
vqci0f npdgfkgguk5w
27 Apr 06
Results of Operations and Financial Condition
12:00am
8-K
EX-99
e69 bpa0iz
12 Feb 13
Results of Operations and Financial Condition
12:00am
8-K
EX-99.1
c3g51xk
24 Jul 19
Innoviva Reports Second Quarter 2019 Financial Results
4:09pm
8-K
EX-99.1
78vgs3e hz
30 Oct 19
Innoviva Reports Third Quarter 2019 Financial Results
4:11pm
8-K
EX-99.1
e49ld 4j662
1 May 19
Innoviva Reports First Quarter 2019 Financial Results
4:25pm
8-K
w8ooerqei1 7ft
8 Mar 22
Innoviva Announces Proposed Offering of $200 Million of Convertible Senior Notes
5:15pm
8-K
EX-99.1
kne943bznuq3 m6z8hpm
29 Apr 20
Innoviva Reports First Quarter 2020 Financial Results
4:06pm
8-K
EX-99.2
mupjzxbh
8 Mar 22
Innoviva Announces Proposed Offering of $200 Million of Convertible Senior Notes
5:15pm
8-K
EX-99.1
6e97a
5 Feb 20
Innoviva Reports Fourth Quarter 2019 Financial Results
4:31pm